ABSTRACT
INTRODUCTION
Herpes simplex virus type 1 (HSV-1) plasmid vectors (5) or PCR products have a number of attractive features for gene transfer into neurons for both gene therapy of neurological disorders and the genetic analysis of neuronal physiology. Consequently, a growing number of investigators have used this vector system to modify neuronal physiology, and changes in behavior have been observed in some studies (4) . Gene transfer with vector stocks prepared using a helper virus results in significant cytopathic effects and immune responses (7) ; therefore, we developed a helper virus-free packaging system for HSV-1 plasmid vectors (3) . A set of 5 cosmids that represents the HSV-1 genome (2) was modified by deletion of the DNA cleavage/packaging sites (contained in the a sequences). Cotransfection of this modified cosmid set and an HSV-1 vector [contains HSV-1 origin of replication (ori) s and a DNA cleavage/packaging site] into fibroblast cells results in the packaging of vectors into HSV-1 particles, but no helper virus is produced (3) . Upon injection into the rat brain, the helper virus-free vector stocks produce substantially less cytopathic effects and cell infiltration than previously observed with helper virus systems. The recent development of bacterial artificial chromosomes that harbor the HSV-1 genome may enhance the use of this system (17) .
HSV-1 plasmid vectors have a number of potential advantages. In particular, the large size of the HSV-1 genome suggests that large vectors might be developed. HSV-1 plasmid vectors are packaged as head-to-tail concatamers that form a genome sized (~ 152 kb) DNA molecule. Thus, large vectors, such as 30 or 50 kb, that can form concatamers of approximately 150 kb might be correctly packaged. However, with helper virus packaging systems, competition between the vector and the helper virus is thought to result in a selective pressure for deletions in large vectors. Vectors (15 or 16 kb) have been correctly packaged using helper virus systems (10, 16) , but a 19 kb vector is subject to spontaneous deletions (10) . However, a 30 kb vector that was stably maintained in a cell line using the Epstein-Barr virus (EBV) oriP-EBNA1 system has been successfully packaged using a helper virus (19) . Because the helper virus-free packaging system may reduce or eliminate the competition between the vector and the helper virus during the packaging procedure, it is conceivable that large vectors might be successfully packaged in this system. Nonetheless, a 16 kb vector is the largest vector that has been reported to be packaged using this system (20) .
In this study, we investigated the properties of a large HSV-1 vector in the helper virus-free system. We constructed a 51 kb HSV-1 plasmid vector that expresses the Escherichia coli Lac Z gene from a neurofilament heavy subunit (NFH) promoter and contains a 40 kb fragment of Saccharomyces cerevisiae DNA. This vector was packaged into HSV-1 particles using our helper virus-free packaging system (3, 18) , and the structure of the packaged vector DNA was verified by both PCR and Southern blot analyses. A vector stock was microinjected into the striatum, the rats were sacrificed at 4 days after gene transfer and X-gal positive cells (>500 per rat) were observed. The principles used to construct this 51 kb vector may support the routine construction of large vectors.
MATERIALS AND METHODS

Vector Construction
pNFHlac, which contains a 0.6 kb fragment of the mouse NFH promoter from plasmid pH-615 (14), has been described (20) .
A 51 kb HSV-1 vector ( Figure 1 ) was constructed in several stages. . The 5 ′ PCR product was digested with Apa I and Eco RI, the 3 ′ PCR product was digested with Eco RI and Sal I, and these 2 fragments were inserted between the Apa I and Xho I sites in pBRlinker-neo (pBR-neo-Sac).
Next, a 4.7 kb BamHI fragment that contains the transcription unit from pNFHlac was inserted into the BamHI site of pBR-linker-neo (pBR-NFHlacZ; two orientations are possible and pBRNFHlacZ contains the 3 ′ end of the NFHlac transcription unit adjacent to Experiment 1 was a small-scale packaging for an initial test of the vectors, and experiments 2 and 3 were large preparations to produce vector stocks for both DNA characterization and microinjection into the rat brain. a Crude, the vector stock obtained from the packaging. b Purified, the vector stock after purification (11) . c ND, not done. the 5 ′ end of the neo r gene). We combined a 2.6 kb Pvu I and Xba I fragment from pBR-neo-Sac (the PCR products and a portion of the amp r gene), a 3.1 kb Pvu I and Not I fragment from pBR-linker and a 6.2 kb Not I and Xba I fragment from pBR-NFHlacZ (the NFHlac transcription unit and the neo r gene) to yield pBR-Sac-NFHlac-neo. A 40 kb fragment of S. cerevisiae DNA was inserted into pBR-Sac-NFHlac-neo (pBRSac40kb-NFHlac-neo) by in vivo recombination cloning in E. coli BJ5183 cells (1, 9) . The three fragments used in this cloning were pBR-Sac-NFHlac-neo digested with Xho I and treated with calf intestinal phosphatase, the 6.1 kb Xmn I fragment from C8179 (nt 140-6258) and the 36.9 kb Spe I fragment from C8179 (nt 3917-40 771).
Miniprep DNA was isolated from the candidates, analyzed by restriction endonuclease digestion and DNA from a correct candidate was transferred into JM109 for large-scale preparation of DNA. Next, a Hin dIII and BamHI fragment that contains 3 polyadenylation sites (TriA cassette) (12) was inserted between the Hin dIII site and a Xho II site (at the boundary between the HSV-1 a sequence and the polyadenylation site) in pHSVpUC (6) to obtain pHSVpUC/ TriA. Two oligonucleotides (5 ′ -CTAGT -GAATTCGGATCCTTAATTAAGTC -GACGC-3 ′ and 5 ′ -GGCCGCGTCGA -CTTAATTAAGGATCCGAATTCA-3 ′ ) were inserted between the Spe I and Not I sites of pHSVpUC/TriA (pHSVpUClinker-I), and then two oligonucleotides (5 ′ -GGCCGCGATATCCGATCGGGA-TCCGGCGCGCCTTAATTAAC-3 ′ and 5 ′ -GATCGTTAATTAAGGCGCGCCG -GATCCCGATCGGATATCGC-3 ′ ) were inserted between the Not I and BamHI sites of pHSVpUClinker-I (pHSVpUClinker-II).
The 46 kb Pac I and Not I fragment from pBR-Sac40kb-NFHlac-neo was inserted into pHSVpUC-linker-II that had been digested with the same enzymes to yield pNFHlac-Sac (ligation reactions contained 2:1, 1:1 or 1:2 molar ratios of vector to insert and DNA concentrations of 0.8, 1.2, 1.6 or 2.0 ng/ µ L). Candidates were isolated in DH5 αCompetent cells ™ (Life Technologies, Gaithersburg, MD, USA) on plates that contained 25 µ g/mL neo, grown in LB medium that contained 50 µ g/mL amp and 25 µ g/mL neo, and miniprep DNA was analyzed by restriction endonuclease digestion. Because large-scale DNA preparations from DH5 α cells contained deletions, miniprep DNA was transformed into Epicurian coli ® JM109, SURE ® and XL-10 Gold ™ cells (all from Stratagene, La Jolla, CA, USA) and MAX E FFICIENCYHB101 ™cells (Life Technologies), and pNFHlac-Sac was stably maintained only in HB101. Finally, the pNFHlac-Sac DNA was isolated using the Qiagen maxiprep procedure.
Packaging Vectors into HSV-1 Particles
Vectors were packaged into HSV-1 particles using the helper virus-free packaging system in 2-2 cells (15) as modified to improve the titers (18) . Vector stocks were purified and concentrated as described (11) . They were titered by counting the number of X-gal positive cells obtained at one day after infection of baby hamster kidney fibroblast cells (BHK21). At one day after infection, we observed more X-gal positive cells using BHK cells than us - 
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Stereotactic Injection of HSV-1 Vectors into the Rat Brain
Male Sprague Dawley rats (100-125 g) were used for these experiments. Vector stocks were delivered by stereotactic injection (2 sites, 3 µ L/site) into striatum. Both hemispheres; anteriorposterior (AP) 0.8, medial-lateral (ML) 2.5, dorsal-ventral (DV) 5.5; AP 1.8, ML 2.5, DV 5.5; AP is relative to bregma, ML is relative to the sagittal suture and DV is relative to the bregma-lambda plane (13) . The rats are smaller than those used for the atlas (13) , and the injections sites were verified by cresyl violet staining. These studies were approved by the Children's Hospital IACUC.
Histology
Four days after gene transfer, the rats were anesthetized with chloral hydrate (400 mg/kg, intraperitoneal) and then perfused with 50 mL PBS followed by 200 mL of 4% paraformaldehyde in PBS. The brains were postfixed in 4% paraformaldehyde in PBS (for 4 h at 4°C), cryoprotected in 25% sucrose in PBS (for 2 days at 4°C), and 25 µ m coronal sections were cut on a freezing microtome. Enzymatic staining and immunohistochemistry were performed on free-floating sections. Expression of β -galactosidase ( β -gal) was detected by incubation with X-gal (16); the X-gal reaction was carried out for 3 h at room temperature at pH 7.9.
Using these reaction conditions, rats that received PBS displayed no staining in the striatum, but faintly positive cells were occasionally observed in the red nucleus and in brain vasculature endothelium. Every fourth section was analyzed for expression of β -gal and approximately 10 of these sections contained the X-gal positive cells. Cell counts were performed under 40 × magnification.
RESULTS AND DISCUSSION
Conventional plasmid construction strategies are difficult to use on large molecules; therefore, we used the following strategy (detailed in Materials and Methods) to construct a 51 kb HSV-1 plasmid vector. First, we constructed a small plasmid that contained the neo r gene, the NFHlac transcription unit and two approximately 1 kb fragments of S. cerevisiae DNA that are approximately 40 kb distant from each other. In vivo recombination cloning in E. coli BJ5183 (1,9) was then used to insert an approximately 40 kb S. cerevisiaeDNA fragment. These plasmids lacked HSV-1 vector sequences because the HSV-1 ori s and asequences contain direct repeats that are not stable during the in vivo recombination cloning procedure.
A DNA fragment containing the NFHlac, neo r and S. cerevisiaesequences was then inserted into a HSV-1 vector by DNA ligation, and candidates were isolated using a selection for the neo r gene. The resulting 51 kb HSV-1 vector was designated pNFHlac-Sac (Figure 1) .
pNFHlac-Sac and pNFHlac (10.2 kb), as a control, were packaged into HSV-1 particles using a helper virusfree packaging system. In three experiments (Table 1) , the titers of pNFHlacSac were similar to, or tenfold lower than, the titers of pNFHlac.
DNA was isolated from one stock of pNFHlac-Sac, digested with Pac I and subjected to Southern blot analysis using a hybridization probe from the S. cerevisiae DNA fragment. The pNFHlac-Sac (51 kb) contains one Pac I site. The pNFHlac-Sac (51 kb) is likely to be packaged as a concatamer of 3 copies to yield a DNA molecule close to the size of the 152 kb genome of HSV-1, and Pac I should cut each concatamer one time to yield 51 kb fragments. Because of the large size of the predicted DNA fragment, the transfer from the gel to the membrane was inefficient (measured by ethidium bromide staining; not shown). Nonetheless, the results (Figure 2A ) demonstrated that the DNA packaged into HSV-1 particles contained a large band. This large band co-migrated with the standard; the standard was pNFHlac-Sac plasmid DNA (isolated from E. coli ) that had been digested with Pac I. This result suggests that pNFHlac-Sac was correctly packaged into vector particles; however, we cannot exclude the possibility of small internal deletions that were too small to affect the apparent mobility of the band in the Southern blot analysis. The presence of Lac Z sequences in the DNA isolated from vector particles was demonstrated by performing PCR using primers from the Lac Z gene. The results ( Figure 2B ) showed a band of the predicted size that had a mobility similar to the PCR products obtained using pHSVlac (5) plasmid DNA as the template.
The pNFHlac-Sac vector stock was microinjected into the striatum of 3 rats, the rats were sacrificed at 4 days after gene transfer, and the brains were subjected to X-gal staining. A low-power photomicrograph ( Figure 3A) shows numerous X-gal positive striatal cells, and high power views (Figure 3 , B and C) demonstrate that some of these Xgal positive cells display neuronal morphology. The presence of some X-gal positive cells that lacked neuronal morphology may reflect either limitations of the vector system or that this 600 bp fragment of the NFH promoter lacks some sequences that are important for neuronal-specific expression.
Consistent with the known capability of HSV-1 to be retrogradely transported through axons, we also observed X-gal positive cells in specific areas of neocortex (not shown). Cell counts showed that these 3 rats contained an average of 688 ± 130 (mean ± SD) Xgal positive striatal cells. The gene transfer efficiency was 4.7% [(100 × mean X-gal positive cells)/([infectious vector particles/ µ L] ×µ L injected) = (100 ×688)/(2.4 ×10 3 ×6)], and this gene transfer efficiency is similar to that obtained using smaller vectors such as pHSVlac (3) or pNFHlac (20) . Larger numbers of transduced cells await improvements to the packaging system, and the importance of long-term expression indicates improvements in the promoter and vector system.
The strategy used to construct this 51 kb vector is a general one that may support the routine construction of large HSV-1 vectors. Potential uses of large HSV-1 vectors include the construction of libraries, the characterization of large promoter fragments or large genomic clones and the construction of vectors that co-express multiple genes. For example, co-expression of tyrosine hydroxylase, GTP cyclohyrolase, aromatic amino acid decarboxylase and a vesicular monoamine transporter might support the efficient production and regulated release of dopamine. Thus, co-expression of these four genes might enable an efficacious gene therapy approach to Parkinson's disease.
INTRODUCTION
Purifying plasmid DNA from bacteria is a commonly used procedure that is the basis for cloning, sequencing, functional expression screens and newer applications like gene therapy. Each of these manipulations requires the isolation of plasmid DNA at high purity. Commercial anion exchange columns, even though they are expensive, are widely used for this purpose. Less expensive methods, such as the use of silica oxide, have the disadvantage that bacterial lipopolysaccarides (LPS or endotoxins) are copurified, which can interfere with downstream applications (2,6,7). Furthermore, silica oxide requires the use of chemicals, such as guanidine hydrochloride, that act as chaotropic substances by changing the structure of water and facilitate the binding of DNA to silica oxide (3) . Because many of these applications require iterative plasmid isolations, we wanted to develop a protocol for a plasmid preparation in a 96-well format based on silica oxide as an established and inexpensive DNA binding matrix. At the same time, we sought to obviate the disadvantages of DNA isolation by silica oxide. Here, we describe the implementation of such an experimental protocol.
MATERIALS AND METHODS
Preparation of Silica Oxide
Silica oxide (Sigma, Deisenhofen, Germany) was dissolved in 250 mL water as a 50 mg/mL suspension. After incubation for 30 min, the fines were removed by suction, and the volume was reconstituted. The solution was
